Phase Scientific International, a Hong Kong based biotechnology startup, has announced the successful completion of a $34 million Series A funding round. This represents the largest Series A raise in Asia's diagnostic technology sector since 2019, reflecting robust investor conviction in Phase Scientific's innovative PHASIFY™ technology and ambitious growth strategy.
The funding round is led by a private equity fund managed by Value Partners Group, one of Asia's largest independent asset management firms, with significant backing from new healthcare-focused investors and continued support from existing global backers.
Building on its patented PHASIFY™ urine concentration technology, which captures over ten times more biomarkers than current industry gold standards, Phase Scientific is the only player advancing a pipeline of urine-based liquid biopsy diagnostics.
The company is developing a comprehensive suite of non-invasive tests for early detection of cancers, women's health conditions, and infectious diseases. Unlike traditional invasive screening methods, PHASIFY™ enables convenient, at-home sample collection, empowering proactive health management and preventive care.
Phase Scientific has developed the world's first urine-based HPV test, a major breakthrough that has achieved significant clinical validation and global recognition. In a recent clinical study with Peking University Shenzhen Hospital, the test demonstrated 93.4% sensitivity in detecting CIN2+ lesions—including cervical precancer and cancer—and over 97% concordance with gold-standard physician-collected testing (Roche's Cobas 4800) for HPV types 16 and 18.
